A report released today by RBC Capital Markets about Agile Therapeutics (NDAQ:AGRX) bumps the target price to $10.00

Having a price of $3.69, Agile Therapeutics (NDAQ:AGRX) traded -0.85% lower on the day. With the last close up 1.91% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the same period. Agile Therapeutics has recorded a 50-day average of $3.65 and a two hundred day average of $3.43. Volume of trade was down over the average, with 169,761 shares of AGRX changing hands under the typical 272,962

Reporting a potential upside of 1.71%, RBC Capital Markets bumped up the target of Agile Therapeutics (NDAQ:AGRX) to $10.00

On Wednesday July 19, 2017, H.C. Wainwright released a statement on Agile Therapeutics (NDAQ:AGRX) upped the target price from $0.00 to $10.00 that suggested an upside of 1.06%.

See Chart Below

Agile Therapeutics has a 52 week low of $1.82 and a 52 week high of $7.95 The company’s market cap is currently $0.

About Agile Therapeutics (NDAQ:AGRX)

Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *


thirteen − three =